PanGenex (PGXC) Launches Blog at and Begins Next Phase in Sales and Distribution Plan

Share Article

PanGenex Corporation (Pink Sheets: PGXC) announces the successful launch of a corporate blog at The new blog highlights the importance of Omega-3s and Omega-3 fish oils from fatty fish such as sardines and anchovies and that they have been proven to lower triglycerides and reduce the risk of sudden death by cardiac arrest by between 50-70% per the American Heart Association. LIPIDEME™ and Omeganol™, core products of the PanGenex product line contain the purest Omega-3s available without a prescription and can be key elements in the battle against cholesterol and sudden cardiac arrest.

News Image
As the national sales campaign is implemented and the marketing plan with Incredible Discoveries® for the launch of Calci-CLEAR™ is finalized, we are penetrating the physician marketing through joint ventures and referrals

Since its launch in mid-June, the new web platforms have resulted in over 672,000 impressions of PanGenex and PanGenex affiliated ads across the Internet through Google AdWords. PanGenex forecasts an increase in anticipated web sales as the strategy is seasoned throughout the next several weeks.

"As the national sales campaign is implemented and the marketing plan with Incredible Discoveries® for the launch of Calci-CLEAR™ is finalized, we are penetrating the physician marketing through joint ventures and referrals," explains Jeff Roman, President and CEO of PanGenex. "We had the opportunity to present our product line to some of the best cardiologists in the country, most recently several cardiologists with St. Joseph's Hospital Cardiology Associates outside of Syracuse, New York who will begin recommending LIPIDEME and Omeganol to their patients starting in mid-July."

PanGenex expects to further increase sales by expanding its physician network and finalizing distribution contracts with firms across the country for the distribution of LIPIDEME, Omeganol and future products.

About PanGenex Corporation:

PanGenex is a publicly traded corporation (PINK SHEETS: PGXC) and pursues business opportunities in the $70 billion dollar nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions. Many of our products contain the purest grade of nutraceutical components available anywhere without a prescription. PanGenex markets products through healthcare practitioners, retail establishments and the internet on websites such as, and



This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jeff Roman
Visit website